Hybio Pharmaceutical Co., Ltd. (300199)의 가격은 얼마입니까?

Hybio Pharmaceutical Co., Ltd. (300199)의 가격은 $3.32입니다.

Hybio Pharmaceutical Co., Ltd. (300199)의 시가 총액은 무엇입니까?

Hybio Pharmaceutical Co., Ltd. (300199)의 시가 총액은 $2.93B입니다.

Hybio Pharmaceutical Co., Ltd. (300199) 주당순이익

Established in 1998 and headquartered in Shenzhen, China, Hybio Pharmaceutical Co., Ltd. specializes in the global research, development, manufacturing, and commercialization of therapeutic peptide active pharmaceutical ingredients (APIs) and polypeptide medications. Its diverse product range addresses therapeutic needs such as diabetes (including liraglutide, semaglutide, and exenatide), gastrointestinal and metabolic disorders (with examples like terlipressin, desmopressin, and linaclotide), as well as applications in obstetrics and gynecology (featuring ganirelix, cetrorelix, and atosiban). Additionally, the company supplies custom peptides and provides essential working standards for peptide APIs and their impurities, offering comprehensive support for development initiatives. Beyond products, Hybio extends its expertise through Contract Research Organization (CRO) and an extensive Contract Development and Manufacturing Organization (CDMO) platform. This platform covers peptide API synthesis and purification process optimization, finished dosage form conceptualization, reference standard preparation and rigorous qualification, detailed impurity and product quality analysis, Good Manufacturing Practice (GMP) systems adhering to both EU and FDA benchmarks, and comprehensive regulatory and dossier support for both international and Chinese markets.

연도	EPS	변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.

연도

EPS

변화

제공된 날짜에 대한 데이터가 충분하지 않습니다.

회사	EPS	EPS 차이	국가
MERCK Kommanditgesellschaft auf Aktien MER.SW	-	-	DE
Merck KGaA MRK.DE	-	-	DE
Takeda Pharmaceutical Company Limited 4502.T	-	-	JP
Galderma Group AG GALD.SW	-	-	CH
Sun Pharmaceutical Industries Limited SUNPHARMA.NS	$0.56	-	IN

회사

EPS

EPS 차이

국가